Spiral
Spiral Therapeutics is a clinical-stage biotechnology company founded by Hugo Peris and headquartered in South San Francisco, focused on developing novel therapies for inner ear disorders.
Profile
Develops targeted therapies for hearing loss and balance disorders using specialized drug delivery systems.
Spiral Therapeutics is a clinical-stage biotechnology company founded by Hugo Peris and headquartered in South San Francisco, focused on developing novel therapies for inner ear disorders. The company's $27 million Series B financing in April 2026, led by Gund Investment with participation from Advanced Bionics and a major global pharmaceutical company, underscores growing interest in this underserved therapeutic area. Spiral's lead program, SPT-2101, has shown statistically significant reduction of vertigo in Ménière's disease patients and is preparing for registrational trials.
Their proprietary MICS™ (Minimally-Invasive Cochlear System) platform enables targeted drug delivery to the cochlea, addressing fundamental challenges in treating hearing loss and balance disorders. The strategic partnership with Advanced Bionics combines cochlear implant expertise with Spiral's drug delivery technology. While the inner ear therapeutic market remains underdeveloped, Spiral's approach positions it among few companies tackling this space with both platform technology and clinical-stage assets. The company faces typical biotech risks of clinical trial outcomes and platform validation, but its specialized focus and recent funding provide runway for key milestones.
Who buys this
- Cochlear implant recipients needing adjunct therapies
- Patients with Ménière's disease and other vestibular disorders
- Hospitals and ENT specialists treating inner ear conditions
- Pharmaceutical partners seeking targeted delivery technologies
- Medical device companies developing combination products
Publicly disclosed clients
- Advanced Bionics
Strengths and what to watch
Strengths
- Proprietary MICS platform enables localized drug delivery to the challenging inner ear anatomy
- Clinical validation from lead program SPT-2101 showing vertigo reduction in Ménière's disease
- Strategic partnership with cochlear implant leader Advanced Bionics for combination therapies
Watch for
- High-risk Phase 3 trial outcomes for SPT-2101 in competitive Ménière's disease space
- Platform validation beyond initial indications given inner ear delivery complexities
- Cash runway management with $27M Series B funding in capital-intensive biotech sector
Recent moves
Key Information
- Founded
- 2023
- Headquarters
- South San Francisco
Frequently Asked Questions
What does Spiral Therapeutics specialize in?
Spiral Therapeutics develops targeted therapies for hearing loss and balance disorders. The clinical-stage biotech company focuses on inner ear conditions, using its proprietary MICS™ platform for precise drug delivery to the cochlea. Their lead program SPT-2101 addresses Ménière's disease vertigo symptoms.
How does Spiral's MICS platform work?
Spiral's Minimally-Invasive Cochlear System (MICS) enables targeted drug delivery to the inner ear's complex anatomy. The platform addresses key challenges in treating hearing and balance disorders by precisely administering therapies to the cochlea, potentially improving treatment efficacy while minimizing systemic side effects.
What is SPT-2101 and what does it treat?
SPT-2101 is Spiral's lead drug candidate showing statistically significant vertigo reduction in Ménière's disease patients. The therapy is preparing for registrational trials, targeting this chronic inner ear disorder that causes dizziness, hearing loss, and tinnitus. It represents one of few clinically validated treatments in development.
Who is Spiral Therapeutics partnered with?
Spiral has a strategic partnership with Advanced Bionics, a cochlear implant leader. The collaboration combines Spiral's drug delivery technology with Advanced Bionics' implant expertise to develop combination therapies for hearing loss patients. The partnership was announced alongside Spiral's $27 million Series B funding.
What conditions does Spiral's technology address?
Spiral's therapies target inner ear disorders including Ménière's disease and other balance conditions. Their technology serves cochlear implant recipients needing adjunct treatments and patients with vestibular disorders. The company focuses on underserved therapeutic areas where targeted drug delivery could significantly improve outcomes.
How is Spiral Therapeutics funded?
Spiral raised $27 million in April 2026 Series B financing led by Gund Investment, with participation from Advanced Bionics and a major pharmaceutical company. This funding supports clinical trials for SPT-2101 and platform development, providing runway in the capital-intensive biotech sector.
Sources
- www.prnewswire.com — Series B funding details and Advanced Bionics partnership